Beyond conventional therapy: NOX4 as a promising target in cardiomyopathy

Area of Science:

• Cardiology
• Molecular Biology
• Pathophysiology

Background:

• Cardiomyopathy encompasses heart muscle disorders characterized by structural and functional abnormalities.
• Common types include dilated and hypertrophic cardiomyopathies, with rarer forms like Takotsubo and arrhythmogenic right ventricular cardiomyopathy.
• Pathological mechanisms involve ventricular hypertrophy, fibrosis, and dysfunction, often triggered by stressors and oxidative stress.

Purpose of the Study:

• To explore the role of NADPH oxidase 4 (NOX4)-driven reactive oxygen species (ROS) production in various cardiomyopathy subtypes.
• To synthesize current knowledge on NOX4's function and regulatory mechanisms in cardiac pathophysiology.
• To highlight the therapeutic implications of understanding NOX4 in cardiomyopathy.

Main Methods:

• Review of existing research on NOX4 and its contribution to cardiac pathology.
• Analysis of NOX4's role in generating ROS within cardiomyocytes, particularly in mitochondria.
• Examination of studies investigating the effects of NOX4 inhibition or deletion on cardiac remodeling and function.

Main Results:

• NADPH oxidase 4 (NOX4) is a significant source of ROS in cardiomyocytes, contributing to pathological cardiac remodeling, inflammation, fibrosis, apoptosis, and hypertrophy.
• ROS generated by NOX4 are implicated in the pathophysiology of diverse cardiomyopathy subtypes.
• Inhibition or genetic deletion of NOX4 has been shown to mitigate these detrimental effects.

Conclusions:

• NOX4-mediated ROS production is a critical factor in the progression of cardiomyopathy.
• Targeting NOX4 presents a promising avenue for developing novel therapeutic strategies for cardiomyopathy.
• Further understanding of NOX4's function and regulation is essential for advancing cardiomyopathy treatment.